Henry Schein (NASDAQ:HSIC) CEO Sells $3,106,409.46 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) CEO Stanley Bergman sold 38,346 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $81.01, for a total value of $3,106,409.46. Following the transaction, the chief executive officer directly owned 427,615 shares in the company, valued at approximately $34,641,091.15. This represents a 8.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $82.39 on Monday. The company has a market cap of $9.45 billion, a P/E ratio of 25.20, a P/E/G ratio of 2.44 and a beta of 0.87. The business has a fifty day simple moving average of $77.85 and a 200-day simple moving average of $72.20. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The company had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter in the previous year, the business earned $1.19 EPS. The firm’s revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Institutional Investors Weigh In On Henry Schein

Several hedge funds have recently modified their holdings of HSIC. CYBER HORNET ETFs LLC purchased a new position in Henry Schein in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new position in shares of Henry Schein during the second quarter worth $27,000. Flagship Harbor Advisors LLC purchased a new position in shares of Henry Schein in the fourth quarter valued at $30,000. Federated Hermes Inc. acquired a new stake in Henry Schein during the 4th quarter valued at $32,000. Finally, Los Angeles Capital Management LLC purchased a new stake in Henry Schein during the 4th quarter worth $37,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Reported quarterly results topped expectations (better EPS and revenue growth), which reinforces momentum in the stable dental market and was a primary driver for the stock rise. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Robert W. Baird upgraded HSIC, reflecting increased analyst confidence in growth/valuation after results. Upgrades can support further upside as they attract buy-side attention. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird
• Positive Sentiment: Leerink Partners published a bullish note forecasting strong price appreciation, adding to analyst-driven buying pressure. Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Positive Sentiment: Market reaction to the beat pushed HSIC to a new 12‑month high, signaling momentum traders and momentum-based funds may add exposure. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: A Yahoo/Finance piece notes analysts are re‑assessing HSIC’s growth profile and valuation — useful context but not an immediate directional catalyst. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Neutral Sentiment: Short‑interest data shows an anomalous report (0 shares / NaN change), which appears to be a reporting/data error and is unlikely to meaningfully affect near‑term trading.
• Negative Sentiment: CEO Stanley M. Bergman sold sizable blocks of stock on Feb. 26–27 (combined sale proceeds ~ $4.0M+), which can be perceived negatively by some investors as profit‑taking or reduced insider conviction. SEC filing: Insider sale filing

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on HSIC shares. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. UBS Group boosted their price target on Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Leerink Partners raised their price objective on Henry Schein from $75.00 to $87.00 and gave the stock a “market perform” rating in a report on Tuesday, February 24th. Mizuho boosted their target price on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Finally, Evercore raised their price target on shares of Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Henry Schein has an average rating of “Hold” and an average price target of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.